Network meta-analysis of the prognosis of curative treatment strategies for recurrent hepatocellular carcinoma after hepatectomy

Table 1 Cumulative mean value of 49 arms of studies and patient profiles from 30 articles of curative treatment of recurrent hepatocellular carcinoma after primary liver resection

Arm in study, n	Patient, n1	Male %	Age in yr	HBV (+) %	HCV (+) %	Cirrhosis %	MVI (+) %	rChild A %	Time to recurrence in mo	rTumor size in mm	rTumor (n = 1) %
RH = 17	1405	79.9	56.5 ± 6.8	68.6	33.3	55.8	29.8	78.7	26.0 ± 8.3	25.3 ± 6.8	76.2
RFA = 11	1013	83.2	56.4 ± 5.5	78.5	12.4	59.0	26.6	94.9	18.1 ± 6.5	21.5 ± 4.0	78.6
TACE = 8	1123	86.5	54.6 ± 8.7	73.4	21.7	49.3	30.7	91.7	14.7 ± 6.6	32.2 ± 16.1	62.3
LT = 12	1484	89.1	53.6 ± 5.3	81.7	9.3	68.4	31.6	76.9	19.4 ± 10.4	27.1 ± 8.0	62.2

¹Patients n, cumulated number of patients in subgroup from all studies.

Details of each study are listed in Supplementary Table 1. RH: Repeated hepatectomy; RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization; LT: Liver transplantation; r: Recurrent; HBV: Hepatitis B virus; HCV: Hepatitis C virus; MVI: Microvascular invasion.